Trial Profile
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PIVOTAL
- 10 May 2019 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Results published in the Journal of Gastroenterology and Hepatology
- 05 Aug 2018 Planned End Date changed from 24 Oct 2018 to 20 Dec 2018.